Literature DB >> 6167346

Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture.

L H Einhorn.   

Abstract

The combination of platinum, vinblastine, and bleomycin was first used at Indiana University in 1974. Thirty of 47 patients (64%) survived for 5 years, and 27 (57%) are currently disease free (NED) and cured of their neoplasm. From 1976 to 1978, 78 consecutive patients were entered on a random prospective study that indicated that equal therapeutic results could be achieved with a lower dosage (0.3 mg/kg) of vinblastine. Fifty-two (67%) patients are continuously NED, and 57 (73%) are currently NED for 2 or more years. Our third-generation study, done in conjunction with the Southeastern Cancer Study Group, tested the hypothesis of whether maintenance vinblastine was necessary to ensure optimal cure rates in disseminated testicular cancer. One hundred thirteen patients entered this maintenance study, and the results demonstrated that cure in a far-advanced cancer could be achieved with only 12 weeks of therapy (remission induction) because the relapse rate in such patients was only 7%. The cure rate for patients presenting with locoregional disease (Stages A and B) should approach 100%. Platinum, vinblastine, and bleomycin will regularly produce a 70% complete remission rate, and a further 10% of patients will be rendered NED with surgical resection of residual disease. The relapse rate with four courses of remission induction therapy in a large cooperative group study (Southeastern Cancer Study Group) was only 7%. The high success rate in disseminated disease has allowed the option of high cure rate in Stage B disease (positive retroperitoneal nodes) with or without adjuvant chemotherapy. At Indiana University, 137 patients have been followed with Stage A and B nonseminomatous testicular cancer from 1973 to 1979 with a minimum follow-up of 2 years, and currently 135 are alive and well. Successful treatment strategies in testicular cancer have yielded a cure rate unparalleled in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6167346

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.

Authors:  T A Dunn; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.

Authors:  T A Dunn; H J Schmoll; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 3.  Late relapse of testicular cancer.

Authors:  Martin E Lipphardt; Peter Albers
Journal:  World J Urol       Date:  2004-04-03       Impact factor: 4.226

Review 4.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 5.  Late relapse of testis cancer.

Authors:  Yaron Ehrlich; Eli Rosenbaum; Jack Baniel
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

6.  Chromosomal damage in peripheral blood lymphocytes of patients treated for testicular cancer.

Authors:  E van den Berg-de Ruiter; B de Jong; N H Mulder; G J te Meerman; H Schraffordt Koops; D T Sleijfer
Journal:  Hum Genet       Date:  1990-01       Impact factor: 4.132

Review 7.  High-dose chemotherapy and stem cell transplantation for advanced testicular cancer.

Authors:  Martin H Voss; Darren R Feldman; Robert J Motzer
Journal:  Expert Rev Anticancer Ther       Date:  2011-07       Impact factor: 4.512

8.  Chemotherapy for non-seminomatous germ-cell tumours.

Authors:  P M Wilkinson
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

9.  Chemotherapy trials in recurrent primary intracranial germ cell tumors.

Authors:  J C Allen; G Bosl; R Walker
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

10.  Management of poor-prognosis testicular germ cell tumors.

Authors:  Kiranpreet Khurana; Timothy D Gilligan; Andrew J Stephenson
Journal:  Indian J Urol       Date:  2010 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.